KINS key facts
as of Oct 2026- Manufacturer of skin care products and supplements intended to maintain the balance of bacteria in the body.
- KINS is valued at approximately $61.9M as of Oct 2026 (last reported valuation).
- It has raised $23.6M; the latest was Later Stage VC ($7.3M) in Jul 2025.
- Notable investors include Mitsubishi UFJ Capital, SMBC Venture Capital, SBI Investment, Mizuho Capital, Japan Finance Corporation — 26 tracked in total.
- Status: Privately Held (backing).
KINS's last reported valuation, Jul 2025. Nothing priced has surfaced since.
- ·The complete investor list: 26 names
- ·Watch KINS: the Monday email on marks, rounds and moves
KINS funding rounds
No funding rounds for KINS are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs KINS
26+KINS valuation
KINS's last reported valuation was $61.9 million in Jul 2025. No priced round, secondary trade or fund mark has surfaced since.
KINS investors
26 investors are on record for KINS, including Mitsubishi UFJ Capital, SMBC Venture Capital, SBI Investment and Mizuho Capital.
About KINS
Manufacturer of skin care products and supplements intended to maintain the balance of bacteria in the body. The company's products contain various types of lactic acid bacteria, yeast, and lactic acid bacterium and offer food essences, face masks for moisturizing and face serums, and more, enabling customers with holistic health and wellness through microbiome-friendly formulations.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Tokyo, Japan
- Founded
- 2018
- Employees
- 55
- Website
- yourkins.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.